MALVERN, Pa., June 21, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved to proceed with dosing the high dose of OCU410ST in the dose-escalation phase of the study. OCU410ST (AAV5-hRORA) is a modifier gene therapy candidate ...

Luminance Dependent Navigation Assessment (LDNA)—a more sensitive and specific measurement of function than MLMT used in previous Phase 3 clinical trials—is the primary endpoint for the study. The Phase 3 liMeliGhT study will focus on the proportion of responders, in treated and untreated groups, achieving an improvement of at least 2 Lux levels from baseline in the study eyes. "Each clinical milestone achieved by OCU400 brings us closer to providing a one-time treatment for life to patients living with RP, ...

OCU400 is the Company's gene-agnostic modifier gene therapy product based on nuclear hormone receptor (NHR) gene, NR2E3. NR2E3 regulates diverse physiological functions within the retina—such as photoreceptor development and maintenance, metabolism, phototransduction, inflammation and cell survival networks. Through its drive functionality, OCU400 resets altered/affected cellular gene networks and Luminance Dependent Navigation Assessment (LDNA)—a more sensitive and specific measurement of function than MLM ...

SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon servi ...

NEW YORK, June 6, 2024 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and reminds investors of the June 10, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To Conta ...

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN) and reminds investors of the June 10, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Ocugen To ...

Ocugen, Inc. (OCGN) is having a phenomenal run in the year so far. Shares of the company have skyrocketed 209.6% year to date against the industry's decline of 5.6%. The significant surge can be attributed to its encouraging pipeline progress. Ocugen is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines. The company is developing a modifier gene therapy platform designed to fulfill the significant medical needs related to retinal diseas ...

LOS ANGELES, June 4, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ocugen, Inc. ("Ocugen" or "the Company") (NASDAQ: OCGN) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between May 8, 2020 and April 1, 2024, inclusive (the "Class Period"), are encou ...

NEW YORK, June 3, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ocugen, Inc. (NASDAQ: OCGN) between May 8, 2020 and April 1, 2024, both dates inclusive (the "Class Period"), of the important June 10, 2024 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased Ocugen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs throu ...

文章核心观点 - 公司Ocugen的财务报表从2020年5月8日至今存在重大错报 [1] - 公司Ocugen内部控制不足 [1] 公司概况 - 公司名称为Ocugen Inc. [1] - 公司股票代码为NASDAQ: OCGN [1] 诉讼相关 - 有股东提起集体诉讼 [1] - 诉讼指控公司做出了虚假和误导性陈述,或未披露重大不利信息 [1] - 投资者如果在2020年5月8日至2024年4月1日期间购买了公司股票并遭受重大损失,可以联系律师了解法律权利 [2] - 成为集体诉讼的首席原告的截止日期为2024年6月10日 [2] 律师事务所介绍 - 律师事务所名称为Holzer & Holzer, LLC [3] - 该律所在2021年和2022年被ISS评为证券诉讼领域顶级律所之一 [3] - 该律所专注于全国范围内的股东诉讼和衍生诉讼,多年来帮助受欺骗的股东追回了数亿美元的损失 [3] - 该律所的联系方式为电话(888)508-6832和电子邮箱cholzer@holzerlaw.com [4][5]